Pathogen Inactivation: Reviews, Recommendations & Commentary
Journal Articles
- Jacobs MR, Good CE, Lazarus HM, Yomtovian RA. Relationship between bacterial load, species virulence, and transfusion reaction with transfusion of bacterially contaminated platelets. Clin Infect Dis. 2008 Apr 15;46(8):1214-20.
View abstract > - Murphy WG, Foley M, Doherty C, et al. Screening platelet concentrates for bacterial contamination: low numbers of bacteria and slow growth in contaminated units mandate an alternative approach to product safety. Vox Sang. 2008 Apr 2 (Epub ahead of print).
View abstract > - Alter HJ. Pathogen reduction: a precautionary principle paradigm. Transfus Med Rev. 2008 Apr;22(2):97-102.
View abstract > - Webert KE, Cserti CM, Hannon J, et al. Proceedings of a consensus conference: Pathogen inactivation – making decisions about new technologies. Transfus Med Rev. 2008 Jan;22(1):1-34.
View abstract > - McCullough J. Pathogen inactivation: a new paradigm for preventing transfusion-transmitted infections. Am J Clin Pathol. 2007 Dec;128(6):945-55.
View abstract > - Klein HG, Anderson D, Bernardi MJ, et al. Pathogen inactivation: making decisions about new technologies - preliminary report of a consensus conference. Vox Sang. 2007 Aug;93(2):179-82.
View abstract > - Bryant BJ and Klein HG. Pathogen inactivation: the definitive safeguard for the blood supply. Arch Pathol Lab Med. 2007 May;131(5):719-33.
View abstract >
XXXth International Congress of the International Society of Blood Transfusion (ISBT)
June 7–12, 2008 | Macao, China
- JP Cazenave. European View About Pathogen Inactivation in Labile Blood Products.
Vox Sang 2008;95(Suppl 1):8
XVIIIth ISBT Regional Congress, Asia • November 10 –13, 2007, Hanoi, Vietnam
- JP Cazenave. Models of Increased Safety Measures—Pathogen Inactivation of Labile Products.
Vox Sang 2007;93(S2):19
©
Cerus Corporation. All Rights Reserved.
Use of the INTERCEPT Blood System in the United States is limited by Federal law to investigational use. If you are a resident of the U.S., please click here.
The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located. The INTERCEPT Blood System is CE marked for use with platelets and plasma.
Website design by NetPilot Web Solutions
Use of the INTERCEPT Blood System in the United States is limited by Federal law to investigational use. If you are a resident of the U.S., please click here.
The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located. The INTERCEPT Blood System is CE marked for use with platelets and plasma.
Website design by NetPilot Web Solutions